{"disease":{"id":"cervix","name":"cervix"},"drugs":{"marketed":[{"drug_id":"bevacizumab","indication_name":"Carcinoma of cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"cemiplimab","indication_name":"Malignant tumor of cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Libtayo","generic_name":"CEMIPLIMAB","company_name":"Regeneron Pharmaceuticals ","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"","quality_score":64,"revenue":"1452","mechanism":"Cemiplimab-rwlc binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors."},{"drug_id":"nab-paclitaxel","indication_name":"Malignant tumor of cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"nab-paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":57,"revenue":"368","mechanism":""},{"drug_id":"paclitaxel","indication_name":"Malignant tumor of cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor [EPC]","quality_score":76,"revenue":"368","mechanism":""},{"drug_id":"nabpaclitaxel","indication_name":"Malignant tumor of cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"Nabpaclitaxel","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":null,"revenue":"368","mechanism":"Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division."},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hycamtin","indication_name":"Malignant tumor of cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hycamtin","company_name":"North Eastern German Society of Gynaecological Oncology","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 4, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"norfloxacin","indication_name":"Mixed Gonococcal and Chlamydia Infection of the Cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Mixed Gonococcal and Chlamydia Infection of the Cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"abraxane","indication_name":"Malignant tumor of cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abraxane","company_name":"The First Affiliated Hospital with Nanjing Medical University","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Mixed Gonococcal and Chlamydia Infection of the Cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"avastin","indication_name":"Carcinoma of cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"taxol","indication_name":"Malignant tumor of cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxol","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bleomycin","indication_name":"Malignant tumor of cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Blenoxane","generic_name":"BLEOMYCIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Aspartyl/asparaginyl beta-hydroxylase","drug_class":"Cytoprotective Agent","quality_score":62,"revenue":null,"mechanism":"Bleomycin works by binding to DNA and causing strand breaks, which ultimately leads to cell death."},{"drug_id":"zirabev","indication_name":"Carcinoma of cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."},{"drug_id":"topotecan","indication_name":"Malignant tumor of cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nogitecan","generic_name":"topotecan","company_name":"Novartis","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"topotecan","quality_score":80,"revenue":null,"mechanism":"Topotecan is a topoisomerase inhibitor that prevents DNA re-ligation, causing double-strand DNA damage."},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the cervix","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":21,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04334239","title":"Effectiveness of Care in Certified Cancer Centres in Germany","phase":"","overall_status":"COMPLETED","enrollment_count":670000,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT06043947","title":"Survival Monitoring in Russian Cancer Registries","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"N.N. Petrov National Medical Research Center of Oncology","has_results":false},{"nct_id":"NCT05996783","title":"Cervical Cancer Screening Based on First-void Urine Self-sampling to Reach un(Der)-Screened Women: ScreenUrSelf Trial","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48000,"lead_sponsor_name":"Universiteit Antwerpen","has_results":false},{"nct_id":"NCT07259616","title":"Incidence of Cervical Cancer in HPV-positive Women With Low-grade Cytological Abnormalities","phase":"","overall_status":"COMPLETED","enrollment_count":46079,"lead_sponsor_name":"Gynaecologisch Oncologisch Centrum Zuid","has_results":false},{"nct_id":"NCT05234112","title":"Prevention and Screening Towards Elimination of Cervical Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":30000,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT05022511","title":"Three Birds With One Stone","phase":"NA","overall_status":"COMPLETED","enrollment_count":27099,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT06339606","title":"Pregnancy Repository","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Sunnybrook Health Sciences Centre","has_results":false},{"nct_id":"NCT05149248","title":"Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":6000,"lead_sponsor_name":"Instituto Nacional de Salud Publica, Mexico","has_results":false},{"nct_id":"NCT07091032","title":"Building Connections","phase":"NA","overall_status":"RECRUITING","enrollment_count":3600,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03382158","title":"International PPB/DICER1 Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3400,"lead_sponsor_name":"Children's Hospitals and Clinics of Minnesota","has_results":false},{"nct_id":"NCT04249856","title":"Colposcopy and Dynamic Spectral Imaging (DSI)","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT04022148","title":"The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 Years","phase":"","overall_status":"UNKNOWN","enrollment_count":2800,"lead_sponsor_name":"University of Fukui","has_results":false},{"nct_id":"NCT06323187","title":"Optimization of Cervical Collections in Pregnancy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2600,"lead_sponsor_name":"Dr. Sascha Drewlo","has_results":false},{"nct_id":"NCT05578833","title":"Algorithm for Cervix Carcinoma Screening in CZ Using the Detection of HPV DNA and CINtec Plus","phase":"","overall_status":"COMPLETED","enrollment_count":2426,"lead_sponsor_name":"AeskuLab Pathology Prague","has_results":false},{"nct_id":"NCT05364138","title":"Evaluating Scaleup of an Adapted Breast Cancer Early Diagnosis Program in Rwanda","phase":"","overall_status":"COMPLETED","enrollment_count":2357,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05102240","title":"Development of Clinically High Efficient Platforms for Individualised Treatment of Cervix Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1800,"lead_sponsor_name":"Tata Memorial Hospital","has_results":false},{"nct_id":"NCT06786429","title":"Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":1800,"lead_sponsor_name":"Eunice Dube","has_results":false},{"nct_id":"NCT06284343","title":"The Gynecological Cancer Associated Thrombosis (GynCAT) Study","phase":"","overall_status":"RECRUITING","enrollment_count":1800,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT03195218","title":"HRME in the Screening of Cervical Cancer Precursor Lesions in Brazil (UH3 - Brazil)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1780,"lead_sponsor_name":"Barretos Cancer Hospital","has_results":false},{"nct_id":"NCT04627818","title":"Diagnostic, Therapeutic and Reproductive Aspects of Patients with Mullerian Anomalies","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"University Hospital, Ghent","has_results":false},{"nct_id":"NCT03301493","title":"Genomic Testing and Resulting Medical Decisions","phase":"","overall_status":"COMPLETED","enrollment_count":1500,"lead_sponsor_name":"Arbeitsgemeinschaft medikamentoese Tumortherapie","has_results":false},{"nct_id":"NCT03034434","title":"Cervical Recuperation After Vaginal Delivery","phase":"","overall_status":"COMPLETED","enrollment_count":1384,"lead_sponsor_name":"Rambam Health Care Campus","has_results":false},{"nct_id":"NCT06002126","title":"Optimization of Cervical Cancer Screening Among Women Living With HIV in Latin American Countries","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1002,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false},{"nct_id":"NCT04732546","title":"Diagnostic, Therapeutic and Reproductive Aspects of Patients With Mullerian Anomalies (MULAN)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University Hospital, Ghent","has_results":false},{"nct_id":"NCT05179824","title":"Tempus Priority Study: A Pan-tumor Observational Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Tempus AI","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT04266093","title":"Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05653063","title":"ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":990,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT06416748","title":"Minimally Invasive Simple Hysterectomy in Low Risk Cervical Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":974,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05246761","title":"Balloon Catheter Combined With Oxytocin Induction Among the Pregnant Women With Previous Cesarean Section","phase":"","overall_status":"UNKNOWN","enrollment_count":924,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT05709730","title":"Follow-up of Cell Changes in the Cervix","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":885,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT04300322","title":"Pessary Versus Progesterone in Singletons","phase":"NA","overall_status":"UNKNOWN","enrollment_count":804,"lead_sponsor_name":"Mỹ Đức Hospital","has_results":false},{"nct_id":"NCT02997553","title":"Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":744,"lead_sponsor_name":"Institut de Cancérologie de Lorraine","has_results":false},{"nct_id":"NCT06116019","title":"Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)","phase":"","overall_status":"RECRUITING","enrollment_count":649,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT00193739","title":"Neoadjuvant Chemotherapy Followed by Surgery Versus Concurrent Chemoradiation in Carcinoma of the Cervix","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":635,"lead_sponsor_name":"Tata Memorial Hospital","has_results":false},{"nct_id":"NCT06041555","title":"MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy)","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04312737","title":"Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma Virus","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Hiantis Srl","has_results":false},{"nct_id":"NCT06452004","title":"Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT05738902","title":"Adherence and Compliance to ERAS in Gynecological Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","has_results":false},{"nct_id":"NCT01365169","title":"Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"","phase":"NA","overall_status":"RECRUITING","enrollment_count":590,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02901626","title":"A Randomized Trial of Pessary in Singleton Pregnancies With a Short Cervix","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":544,"lead_sponsor_name":"The George Washington University Biostatistics Center","has_results":true},{"nct_id":"NCT04259762","title":"Enhancing Cancer Prevention and Control Pathways-Native Health Initiative","phase":"NA","overall_status":"COMPLETED","enrollment_count":508,"lead_sponsor_name":"New Mexico Cancer Research Alliance","has_results":true},{"nct_id":"NCT04444206","title":"Prevention of Preterm Birth by Screening of the Consistency Index and Length of the Uterine Cervix in Women With a Single Pregnancy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"University of Campania Luigi Vanvitelli","has_results":false},{"nct_id":"NCT03010150","title":"Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":471,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05764044","title":"Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":365,"lead_sponsor_name":"Hospital do Coracao","has_results":false},{"nct_id":"NCT04534075","title":"Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":354,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT07400809","title":"Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.","phase":"","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Tata Memorial Hospital","has_results":false},{"nct_id":"NCT03256916","title":"Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":348,"lead_sponsor_name":"Tata Memorial Hospital","has_results":false},{"nct_id":"NCT03665688","title":"Comparing Outpatient to Inpatient Cervical Ripening Using Dilapan-S®","phase":"NA","overall_status":"COMPLETED","enrollment_count":338,"lead_sponsor_name":"The University of Texas Medical Branch, Galveston","has_results":true},{"nct_id":"NCT03510273","title":"Honduras Liger Thermocoagulator Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":320,"lead_sponsor_name":"PATH","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}